View in EDS

Characterization of the tautomeric equilibrium of molnupiravir, an antiviral for the treatment of COVID-19.

Saved in:

Bibliographic Details
Title:	Characterization of the tautomeric equilibrium of molnupiravir, an antiviral for the treatment of COVID-19.
Authors:	Burgess SA; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA. Electronic address: samantha.burgess@merck.com., Wang X; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA., Stueber D; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA., Wang Y; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA., Cohen RD; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA., Lam YH; Modeling & Informatics, Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA., Iuzzolino L; Modeling & Informatics, Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA., Reibarkh M; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA. Electronic address: mikhail_reibarkh@merck.com.
Source:	Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2025 Nov 15; Vol. 265, pp. 117025. Date of Electronic Publication: 2025 Jun 13.
Publication Type:	Journal Article
Journal Info:	Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1873-264X
DOI:	10.1016/j.jpba.2025.117025